Table 1. In vitro studies of T-cell responses modulation by IC-activated DC.
| Type of viral determinant | Antigen | Antibody | Immune outcome | Reference |
|---|---|---|---|---|
| Viral proteins | Recombinant HBsAg | Polyclonal Anti-HBSAg (patients sera) | Increased uptake of IC Augmented in vitro proliferation of T cells Augmented production of IFN-γ by T cells | 55 |
| HBsAg (purified from patients) | Polyclonal anti-HBV (patients sera) | Enhanced IL-2 and IFN-γ production by co-cultured T cells | 56 | |
| Recombinant SIV Gag-p55 | Polyclonal anti-p55 (monkeys sera) | Enhanced cross-presentation Induction of anti-Gag-specific CD8+ T-cell responses | 57 | |
| Virions | SIV virions | Highly neutralizing SIVIG (monkeys sera) | Enhanced virus-specific CD4+ T-cell responses | 58 |
| HIV-1 | Polyclonal anti-HIV (patients sera) | Weak stimulating capacity of HIV-specific CTL response | 59 | |
| Infected cells | FrCasE-infected cells | Anti-gp70 mAb | Enhanced proliferation of Gag-specific CD8+ T cells | 43 |
Abbreviations: cytotoxic T lymphocyte, CTL; immune complex, IC; interferon, IFN; interleukin, IL; hepatitis B surface antigen, HBsAg; HBV, hepatitis B virus; human immunodeficiency virus, HIV; polyclonal immune globulin prepared from hyperimmune SIV infecetd animals, SIVIG.